Krebs Biochemicals Key Ratios
NSE: KREBSBIO | BSE: 524518
₹56.73
As on 08-Sep-2026IST
Market cap
₹120 Cr
Revenue (TTM)
₹25 Cr
P/E Ratio
--
P/B Ratio
-0.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 2.57 | 27.42 | -29.72 | -21.45 | -12.39 |
| EBIT | 68.69 | 79.33 | 58.40 | 14.98 | 10.45 |
| Net Profit | -6.24 | 53.31 | 47.97 | 10.69 | 9.11 |
| EPS | -6.24 | 53.31 | 47.97 | 10.69 | 9.52 |
| Book Value | -- | -- | -22.67 | -62.54 | -211.71 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-25 | Mar-24 |
| EBIT-Margin
| -41.24 | -46.69 | -35.47 | -50.14 | -30.72 |
| Net Margin
| -48.93 | -54.43 | -51.43 | -61.20 | -38.78 |
| Return on equity
| 0.00 | 0.00 | -- | 0.00 | 0.00 |
| Return on Capital
| -25.84 | -35.03 | -- | -29.92 | -18.99 |
| Return on Assets
| -13.41 | -17.02 | -8.48 | -15.52 | -11.17 |
| Debt to Equity (x)
| -- | -- | -1.00 | -1.45 | -1.62 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
--
|
-29.92
|
-18.99
|
-28.59
|
-57.38
|
|
Peer Median
|
--
|
16.46
|
15.49
|
17.37
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
9.94
|
13.87
|
14.72
|
15.70
|
--
|
ROA
-8.48
Lower than Peers by 15.75
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
-8.48
|
-15.52
|
-11.17
|
-13.54
|
-25.51
|
|
Peer Median
|
7.27
|
8.04
|
7.19
|
9.43
|
--
|
EBIT Margin
-35.47
Lower than Peers by 44.96
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
-35.47
|
-50.14
|
-30.72
|
-42.85
|
-67.49
|
|
Peer Median
|
9.49
|
10.05
|
10.28
|
13.90
|
--
|
Net Margin
-51.43
Lower than Peers by 60.07
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
-51.43
|
-61.20
|
-38.78
|
-46.81
|
-73.16
|
|
Peer Median
|
8.64
|
9.11
|
6.78
|
10.91
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
0.00
|
-46.75
|
-25.71
|
-34.78
|
-64.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-29.72
Lower than Peers by 36.10
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
-29.72
|
-14.10
|
-3.29
|
-12.68
|
11.18
|
|
Peer Median
|
6.38
|
7.17
|
10.56
|
12.63
|
--
|
EBIT Growth
58.40
Higher than Peers by 58.71
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
58.40
|
-40.21
|
30.66
|
44.56
|
-77.49
|
|
Peer Median
|
-0.31
|
12.05
|
6.17
|
-2.90
|
--
|
Net Profit Growth
47.97
Higher than Peers by 40.39
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
47.97
|
-36.55
|
20.10
|
44.55
|
-57.01
|
|
Peer Median
|
7.58
|
22.15
|
27.97
|
-14.10
|
--
|
EPS Growth
47.97
Higher than Peers by 45.70
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
47.97
|
-36.55
|
20.10
|
44.55
|
-42.89
|
|
Peer Median
|
2.27
|
8.80
|
--
|
-3.68
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
--
|
-22.67
|
-19.86
|
-32.45
|
-60.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-1.00
Lower than Peers by 1.03
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
-1.00
|
-1.45
|
-1.62
|
-1.84
|
-1.91
|
|
Peer Median
|
0.02
|
0.03
|
0.05
|
0.14
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
--
|
-0.35
|
-0.08
|
-0.10
|
-0.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.09
Lower than Peers by 2.36
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
0.09
|
0.10
|
0.28
|
0.33
|
0.45
|
|
Peer Median
|
2.45
|
2.20
|
1.93
|
1.82
|
--
|
Quick Ratio
0.03
Lower than Peers by 1.68
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
0.03
|
0.04
|
0.12
|
0.08
|
0.13
|
|
Peer Median
|
1.72
|
1.72
|
1.59
|
1.30
|
--
|
Interest Coverage
-0.93
Lower than Peers by 10.72
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
-0.93
|
-3.55
|
-3.21
|
-7.30
|
-7.26
|
|
Peer Median
|
9.79
|
12.28
|
12.45
|
16.98
|
--
|
Operating Efficiency
Debtors to sales
0.02
Lower than Peers by 26.99
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
0.02
|
0.12
|
3.77
|
1.01
|
1.47
|
|
Peer Median
|
27.00
|
26.23
|
23.97
|
24.57
|
--
|
Asset Turnover
0.15
Lower than Peers by 0.52
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
0.15
|
0.25
|
0.29
|
0.29
|
0.34
|
|
Peer Median
|
0.67
|
0.74
|
0.88
|
0.82
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
--
|
8.23
|
8.79
|
4.91
|
3.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
--
|
66.69
|
78.69
|
131.30
|
128.88
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
--
|
1,219.44
|
948.90
|
378.02
|
263.51
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
--
|
-1,144.52
|
-861.42
|
-241.81
|
-131.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-8.52
Lower than Peers by 64.35
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
-8.52
|
--
|
--
|
--
|
--
|
|
Peer Median
|
55.83
|
39.17
|
40.74
|
25.97
|
--
|
Price / Book Value
-0.72
Lower than Peers by 5.56
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
-0.72
|
-0.98
|
-1.10
|
-1.22
|
-4.12
|
|
Peer Median
|
4.84
|
3.61
|
3.87
|
2.79
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.14
|
0.19
|
0.20
|
0.65
|
--
|
EV/EBITDA
-944.60
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
-944.60
|
-24.86
|
-39.30
|
-20.11
|
-13.77
|
|
Peer Median
|
--
|
28.79
|
25.41
|
15.07
|
--
|
Market Cap
120
Lower than Peers by 6,069
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Krebs Biochemicals
|
120
|
144
|
132
|
122
|
309
|
|
Peer Median
|
6,189
|
3,944
|
2,959
|
3,742
|
--
|